心力衰竭恢复中的微血管机制
本研究通过分析LVAD植入前后心肌组织,结合小鼠模型与谱系追踪,发现心力衰竭恢复伴随纤维化减少和毛细血管密度增加,并鉴定出一类成纤维细胞可转变为内皮细胞,促进血管新生。c-Myc是调控该细胞命运转换的关键因子,为心衰再生治疗提供了新靶点。
要点
- LVAD支持后心肌纤维化减少、毛细血管密度增加,提示血管新生参与恢复。
- 成纤维细胞向内皮细胞转变( mesenchymal-to-endothelial transition)是微血管修复的重要机制。
- c-Myc可调控该细胞命运转换,是潜在治疗靶点。
核心结论
- 心力衰竭恢复伴有纤维化减少和微血管化增强,部分由成纤维细胞向内皮细胞命运转换驱动。
- c-Myc是该转换的调节因子之一,为开发心衰再生疗法提供机制切入点。
研究设计与样本
- 获取心衰患者LVAD植入时及取出时心肌组织,进行组织学分析和单核RNA测序。
- 结合小鼠心衰恢复模型和谱系示踪研究,以及患者来源心肌非肌细胞培养系统。
主要发现
- LVAD取出后心肌组织纤维化减少、毛细血管密度增加。
- 成纤维细胞丰度与内皮细胞丰度呈负相关,与恢复期血管新生增强一致。
- 单核RNA测序鉴定出倾向于发生间充质-内皮转变的成纤维细胞亚群。
- LVAD后非肌细胞增殖和血管生成能力增强,形成血管样结构。
- c-Myc敲低使LVAD后非肌细胞回复到LVAD前状态,过表达则使LVAD前细胞获得LVAD后表型。
关键数值与推荐
- LVAD后样本纤维化减少,毛细血管密度增加。
- 成纤维细胞丰度与内皮细胞丰度呈负相关。
- c-Myc敲低或过表达实验表明其参与细胞命运转换。
- 小鼠模型显示微血管灌注增加。
临床怎么用
- 该研究为理解LVAD介导的心衰恢复提供了细胞和分子机制。
- c-Myc可作为潜在靶点,用于开发促进血管新生和心肌恢复的治疗策略。
局限性
- 患者样本量未明确,具体数值如纤维化程度、毛细血管密度变化幅度、c-Myc影响的具体定量结果、样本量、P值均未在摘要中提供。
- 主要基于转录组和细胞实验,体内功能验证仅限于小鼠模型,人体内c-Myc调控的完整机制仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure (HF) is a significant global health problem. Left ventricular assist device (LVAD) implantation serves as a bridge for patients awaiting heart transplantation. Intriguingly, LVAD support often improves cardiac histology and function, sometimes enough to avoid transplantation after LVAD removal. However, the cellular programs underlying this recovery remain unclear. METHODS: Myocardial tissues were obtained from patients with HF at the time of LVAD implantation (pre LVAD) and explantation (post LVAD) for histological analysis and single-nucleus RNA sequencing. A murine model of HF recovery, combined with lineage tracing studies, was employed to define cellular sources of vascular repair. Cardiac function, fibrosis, and vascular density were assessed using echocardiography, histology, and fluorescent microsphere perfusion. A patient-derived cardiac nonmyocyte culture system was established to interrogate mechanisms of cell fate regulation. RESULTS: Post-LVAD myocardial tissues exhibited reduced fibrosis and increased capillary density compared with pre-LVAD samples. Across samples, fibroblast abundance was inversely correlated with endothelial cell abundance, consistent with enhanced angiogenesis during recovery. Single-nucleus RNA sequencing identified a fibroblast subset predisposed to undergo mesenchymal-to-endothelial transition, acquiring an endothelial cell identity. Additionally, nonmyocytes from pre-LVAD hearts proliferated poorly and failed to form vascular structures, whereas nonmyocytes from post-LVAD hearts displayed greater proliferation and angiogenesis capacity, forming vessel-like structures, reinforcing the association of HF recovery with angiogenic reprogramming. Mechanistically, knockdown of c-Myc (cellular myelocytomatosis oncogene) by small interfering RNA shifted post-LVAD nonmyocytes to a pre-LVAD-like state, while c-Myc overexpression by mRNA in pre-LVAD cells induced a post-LVAD-like phenotype, implicating c-Myc as 1 contributor to this fate switch. A model of HF recovery in mice mimicked the histological and functional changes in patients, with physiological evidence of increased microvascular perfusion, associated with a fibroblast-to-endothelial transition, documented by lineage tracing. CONCLUSIONS: HF recovery involves reduced fibrosis and enhanced microvascularization, partly driven by fibroblast-to-endothelial cell fate transition. c-Myc functions as 1 regulator of this transition, offering a mechanistic entry point to develop regenerative therapies in HF.
引用
- Li, Gupta, Ranka, et al. Recovery From Heart Failure: Microvascular Mechanisms. Circulation. 2026. PMID: 41878819. doi:10.1161/CIRCULATIONAHA.125.078996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。